Illumina vs 10x Genomics Which Is a Better Investment?

Illumina and 10x Genomics are two leading companies in the genomics industry, with both stocks being closely watched by investors. Illumina is a pioneer in DNA sequencing technology, while 10x Genomics is known for its innovative single-cell analysis solutions. The competition between these two companies has intensified in recent years, with investors closely monitoring their financial performance, product development, and market share. In this analysis, we will delve into the key factors influencing the stock performance of Illumina and 10x Genomics.

Illumina or 10x Genomics?

When comparing Illumina and 10x Genomics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and 10x Genomics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while 10x Genomics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, 10x Genomics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.43 and 10x Genomics's P/E ratio at -9.39. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 10.76 while 10x Genomics's P/B ratio is 2.37.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while 10x Genomics's is -0.52%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and 10x Genomics's ROE at -25.12%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $140.29 for Illumina and $14.06 for 10x Genomics. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. 10x Genomics's prices fluctuated between $12.95 and $57.90, with a yearly change of 347.10%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.